Skip to main content Skip to main navigation menu Skip to site footer

A severe COVID-19 patient with diabetes mellitus getting dexamethasone with depression disorders: a case report

  • Ammar Ammar ,
  • Musofa Rusli ,


Background: Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 coronavirus requires host cells to replicate, leading to rapid and uncontrollable viral replication and could end in increased production of pro-inflammatory cytokines. This case study aims to evaluate a severe COVID-19 patient with diabetes mellitus getting dexamethasone with depression disorders.

Case Presentation: A-56 years old Javanese female who lives in Sidoarjo was admitted to the emergency room of Dr. Soetomo Public Regional Hospital, Surabaya due to shortness of breath from the patient’s anamnesis. The shortness of breath was getting worse in the last 3 days before being admitted to the hospital. The patient had a fever in the previous 3 days before being admitted to the hospital. She also had a cough with phlegm for 1 week before being admitted to the hospital. The patient’s condition is oxygen saturation at 93% with a simple mask 6-8 lpm (oxygen saturation at 72% in free air. Her medical history revealed that she had suffered from diabetes since approximately 8 years ago and routinely took 5 mg of glibenclamide once a day. She also had high blood pressure from 5 years ago and routinely took 10 mg of amlodipine once a day. Treatment for this patient in severe condition requires comprehensive management such as symptomatic therapy, oxygenation, and adequate nutritional therapy. In addition, the patient received dexamethasone and antidepressant drugs such as fluoxetine 10 mg.

Conclusion: The oxygenation therapy, symptomatic, antiviral, supportive, and adequate nutritional treatment can improve the clinical outcome regarding a severe COVID-19 patient with diabetes mellitus getting dexamethasone with depression disorders. 


  1. Tu H, Tu S, Gao S, Shao A, Sheng J. Current epidemiological and clinical features of COVID-19; a global perspective from China. J Infect. 2020;81(1):1-9.
  2. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449-1458.
  3. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23.
  4. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis IG, et al. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021;21(2):167-179.
  5. Pennica A, Conforti G, Falangone F, Martocchia A, Tafaro L, Sentimentale A, et al. Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review. SN Compr Clin Med. 2020:1-6.
  6. Zhou C, Gao C, Xie Y, Xu M. COVID-19 with spontaneous pneumomediastinum. Lancet Infect Dis. 2020;20(4):510.
  7. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273.
  8. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574.
  9. Wang J, Zhou M, Liu F. Reasons for healthcare workers becoming infected with novel coronavirus disease 2019 (COVID-19) in China. J Hosp Infect. 2020;105(1):100-101.
  10. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;80(5):e1-e6.
  11. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. AJR Am J Roentgenol. 2020;215(1):87-93.
  12. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20(4):425-434.
  13. Johnson RM, Vinetz JM. Dexamethasone in the management of covid -19. BMJ. 2020;370:m2648.
  14. Frid AH, Kreugel G, Grassi G, Halimi S, Hicks D, Hirsch LJ, et al. New Insulin Delivery Recommendations. Mayo Clin Proc. 2016;91(9):1231-55.
  15. Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes. 2015;6(8):1073-1081.
  16. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
  17. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.
  18. Gautam S, Jain A, Gautam M, Vahia VN, Grover S. Clinical Practice Guidelines for the management of Depression. Indian J Psychiatry. 2017;59(Suppl 1):S34-S50.

How to Cite

Ammar, A., & Rusli, M. (2022). A severe COVID-19 patient with diabetes mellitus getting dexamethasone with depression disorders: a case report. Bali Medical Journal, 11(1), 67–72.




Search Panel